Comparison
Retatrutide activates three incretin-related receptors while semaglutide targets GLP-1 only — the difference in receptor breadth drives substantial differences in reported metabolic outcomes.
Semaglutide is marketed as Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (oral). Retatrutide has no approved brand name and remains in Phase 2 clinical trials.
| Attribute | Retatrutide | Semaglutide |
|---|---|---|
| Full name | Retatrutide (LY3437943) | Semaglutide (Ozempic / Wegovy / Rybelsus) |
| Class | Triple agonist (GLP-1 / GIP / glucagon) | GLP-1 receptor agonist (mono-agonist) |
| Mechanism | Simultaneous activation of GLP-1, GIP, and glucagon receptors | Selective GLP-1 receptor agonism — increases insulin secretion, reduces glucagon, slows gastric emptying, promotes satiety |
| Half-life | ~6 days | ~1 week (subcutaneous); shorter with oral form |
| Commonly reported doses | 2–12 mg/week SubQ | 0.25–2.4 mg/week SubQ; oral 3–14 mg/day |
| Routes | SubQ | SubQ, oral |
| Primary reported use | Investigational metabolic and weight research | FDA-approved for T2D and obesity (Ozempic / Wegovy); oral form approved (Rybelsus) |
The most fundamental distinction is receptor breadth. Semaglutide's mechanism is well characterised around GLP-1 agonism alone, producing satiety signalling, glucose-dependent insulin release, glucagon suppression, and slowed gastric emptying. Retatrutide adds two further receptor targets: GIP, which modulates adipocyte activity, promotes fat storage redistribution, and potentiates the glucose-lowering action of insulin; and glucagon, which raises energy expenditure through thermogenesis and drives hepatic glucose output — an effect that counteracts some of the hypoglycaemic risk of the other two arms.
Research has investigated both compounds for their potential role in weight reduction, and the magnitude of effect differs. Phase 2 data for retatrutide showed greater weight reduction percentages than semaglutide in a comparative context: semaglutide 2.4 mg (Wegovy) produced approximately 15% body weight reduction across the STEP trial programme; phase 2 data for retatrutide at its highest commonly reported doses showed up to approximately 24% body weight reduction. A direct head-to-head phase 3 comparison is not yet available, and differences in trial populations, titration schedules, and duration make indirect comparisons exploratory rather than definitive.
Availability and depth of evidence base differ substantially. Semaglutide has one of the strongest evidence bases in contemporary metabolic medicine, with completed phase 3 programmes, cardiovascular outcome trial data (SUSTAIN-6 for T2D, SELECT for cardiovascular risk reduction), renal protection signals, and years of post-marketing real-world safety data. Retatrutide remains at phase 2 only, with longer-term safety characterisation, organ-level outcomes, and comparative efficacy data still pending.
Semaglutide acts exclusively at the GLP-1 receptor. GLP-1 receptor agonism produces: glucose-dependent insulin secretion from pancreatic beta cells; suppression of glucagon from alpha cells; slowed gastric emptying that attenuates postprandial glucose excursions; central satiety signalling via hypothalamic and brainstem pathways; and documented cardioprotective effects thought to involve direct GLP-1 receptor expression in cardiac and vascular tissue.
Retatrutide adds GLP-1 agonism alongside two additional receptor arms. GIP receptor activation modulates adipocyte lipid handling and storage, potentiates glucose-stimulated insulin secretion in synergy with GLP-1, and may influence bone metabolism. Glucagon receptor agonism — which in isolation would raise blood glucose — appears in this context to contribute net energy expenditure benefit via increased thermogenesis and enhanced hepatic fatty acid oxidation, with the glucose-raising effect offset by the dominant insulin-secreting actions of GLP-1 and GIP. The combined triple-agonist pharmacology is thought to underlie the amplified metabolic effect seen in early phase data.
Research has investigated both compounds for their potential role in metabolic health, obesity, and type 2 diabetes management. Semaglutide additionally has robust data in cardiovascular risk reduction (SELECT trial, demonstrating reduced major adverse cardiovascular events in non-diabetic patients with obesity) and emerging renal protection signals. Anecdotal reports suggest improvement in body composition and glycaemic control with both agents.
Retatrutide's triple mechanism introduces additional receptor biology whose organ-level consequences are still being characterised. The glucagon arm in particular raises questions about long-term hepatic and bone effects that phase 3 programmes will be designed to answer.
Semaglutide (SubQ): Commonly reported protocols begin at 0.25 mg once weekly for the first four weeks, stepping up through 0.5 mg and 1 mg intervals towards a maintenance dose; for the obesity indication (Wegovy), the commonly reported maintenance target is 2.4 mg/week reached over approximately 16–20 weeks of titration. Commonly reported doses range from 0.25 mg to 2.4 mg per week.
Semaglutide (oral): Commonly reported doses range from 3 mg to 14 mg daily, taken on an empty stomach with no more than 120 mL of water; bioavailability is substantially lower than the subcutaneous route.
Retatrutide: Commonly reported protocols in phase 2 research start at 2 mg once weekly, with slower titration steps to higher doses; commonly reported doses range from 2 mg to 12 mg per week. The titration is typically more conservative than semaglutide given the broader receptor activation and greater GI sensitivity during dose escalation.
Both compounds are available as subcutaneous injectable formulations administered once weekly. Semaglutide has the additional option of oral administration (Rybelsus), offering a needle-free route at the cost of reduced bioavailability and strict fasting requirements. Retatrutide is currently available in subcutaneous form only within the context of clinical research.
Reported side effects in research and anecdotal accounts for both compounds include nausea, vomiting, constipation, diarrhoea, reduced appetite, and fatigue — the characteristic GI profile of incretin-based therapies. These effects are most prominent during dose escalation and typically attenuate with time at stable doses.
Semaglutide carries a documented, though rare, pancreatitis signal from post-marketing surveillance and trial data; there is also a class-related thyroid C-cell concern identified in rodent models (clinical significance in humans remains under study). Retatrutide's full side effect profile is still being characterised in ongoing phase 2 and anticipated phase 3 programmes. The glucagon receptor arm introduces theoretical considerations around hepatic effects and bone turnover that are subjects of active investigation.
Semaglutide is preferred in research and clinical contexts where established evidence, regulatory approval, and long-term safety data are the priority. Its approval across multiple indications (T2D, obesity, cardiovascular risk) and the breadth of available outcome data make it the reference compound for GLP-1 agonist research.
Retatrutide is chosen by researchers specifically interested in characterising the additive or synergistic contribution of GIP and glucagon receptor pathways to metabolic outcomes — particularly where the ceiling effect of GLP-1 mono-agonism is a study variable or where maximum weight reduction magnitude is a research endpoint.
Combining retatrutide and semaglutide is not a commonly reported protocol. Both compounds agonise the GLP-1 receptor, meaning stacking them does not add a complementary or orthogonal mechanism — it simply risks cumulative GI side effects, including intensified nausea and vomiting, without a plausible additive benefit. Researchers investigating incretin biology typically select one agent — either a mono-agonist or a multi-agonist — aligned with the specific receptor combination they aim to study.
Researchers commonly choose semaglutide when a well-documented, regulatory-approved GLP-1 agonist with extensive long-term safety data is the research priority. Its multi-year real-world evidence base, cardiovascular outcome data, and broad indication approval make it the established reference point for GLP-1 biology in metabolic research.
Researchers commonly choose retatrutide when the specific interest is investigating the additive contribution of GIP and glucagon receptor pathways to metabolic outcomes — particularly in studies where maximising weight reduction magnitude or characterising the unique pharmacology of triple-agonism is the central question. Its current phase 2 status means researchers engaging with it are operating in an investigational, data-generating context.
Does retatrutide cause more side effects than semaglutide?
The GI side effect profile — nausea, vomiting, constipation, and diarrhoea — is similar in class and present with both compounds. Retatrutide's full safety profile is still under investigation in phase 2 and upcoming phase 3 trials; a definitive comparative safety assessment between the two agents is not yet available from completed trial data.
Is retatrutide available for purchase?
Retatrutide is not approved by any major regulatory authority and is not commercially available through licensed pharmaceutical channels. Availability varies by jurisdiction and it remains investigational. Semaglutide, by contrast, is prescription-approved in most countries under the Ozempic, Wegovy, and Rybelsus brand names.
Which shows greater weight loss in research?
Phase 2 retatrutide data showed greater percentage body weight reduction (up to approximately 24% at highest doses) compared to semaglutide's approximately 15% in the STEP trials. However, direct phase 3 head-to-head comparison data is not yet available, and differences in trial design, population, and titration schedules mean indirect comparisons should be interpreted as exploratory.